Japan Tobacco/Roche Dyslipidemia Drug Poses Blockbuster Potential - JT Senior Executive
This article was originally published in PharmAsia News
Executive Summary
Japanese industry conglomerate Japan Tobacco Senior Executive VP and pharmaceutical business President Noriaki Okubo said the company's dyslipidemia drug candidate, cholesterol ester transfer protein inhibitor JTT-705 could grow to be a ¥100 billion blockbuster drug